Skip to main content
. 2024 Jun 11;10:278. doi: 10.1038/s41420-024-02040-0

Fig. 8. PDD treatment induces prexasertib-induced NAD+ depletion and reduces cancer cell stemness in OC cells.

Fig. 8

A NAD+ assay shows PDD treatment together with 1 µM prexasertib showed more reduced levels of cellular NAD+ compared to prexasertib individual treatment in OVCAR8 cells. B Represeantative AldeFluor assay shows depleted ALDH positive cells while treated 5 µM PDD compared to DMSO treated control in OC cells. DEAB was used here is an ALDH negative control. C, D Histogram representation of percentage of ALDH-positive cells treated with DEAB, DMSO, and 5 µM PDD in OVCAR8 and SKOV3, respectively. E Immunoblot study showing the protein expression level of ALDH1A1 while OC cells were treated with DMSO, 5 nM prexasertib, 5 µM PDD, and their combination. All the experiments were done in triplicates and the error bars represent the standard deviation from three independent experiments. F Hypothetical/working model illustrating the synergetic lethality with CHK1 and PARG inhibition in ovarian cancer (OC) cells. One-way ANOVA with Tukey’s multiple comparison test for NAD+ assay and Dunnett’s T3 multiple comparison test for AldeFluor assay were performed to analyze the statistical significance. n.s. not significant; *p < 0.05; ***p < 0.001; ****p < 0.0001.